News • Breast biopsy

Hologic's Brevera system receives European CE mark

Transformational workflow solution offers real-time imaging of tissue samples, resulting in major cost and time savings

Brevera breast biopsy system with CorLumina imaging technology.
Source: Hologic

Hologic, Inc. announced it has obtained a CE Mark in Europe for the Brevera breast biopsy system with CorLumina imaging technology, a groundbreaking real-time breast biopsy and verification system that improves the patient experience and streamlines the biopsy process from start to finish. The first-of-its-kind Brevera system is designed to increase biopsy accuracy with real-time imaging that delivers valuable information at the point of care, enabling clinicians to make informed decisions with confidence.

The Brevera system is the world’s first and only breast biopsy solution to combine tissue acquisition, real-time imaging, sample verification and advanced post-biopsy handling in one, integrated system. Designed for 2D and 3D breast biopsy, the innovative system allows clinicians to perform fast and efficient procedures that save costs and improve the patient experience.1 The new product represents another major advance in Hologic’s ongoing efforts to improve patient satisfaction and workflow in the biopsy suite.

The Brevera system is a major breakthrough that transforms the breast biopsy procedure as we know it

Jan Verstreken

Until now, radiologists performing stereotactic breast biopsy procedures to diagnose breast cancer were often required to leave the patient under compression while they moved to another room to image and verify tissue samples. This leads to lengthy procedure times and anxious, uncomfortable patients, and can interrupt facility screening schedules. With the Brevera system, radiologists are able to obtain and image tissue samples in the procedure room in just a few seconds, potentially saving up to 10 minutes per patient and cutting the procedure time by up to 25 percent.2 “The Brevera system is a major breakthrough that transforms the breast biopsy procedure as we know it,” said Jan Verstreken, Hologic’s President for EMEA and Canada. “Clinicians are now able to image and verify tissue samples in real-time in the procedure room, leading to fast procedure times and an improved experience for women, without compromising accuracy or outcomes. The Brevera system is yet another example of Hologic’s dedication to developing products that are designed to better meet the needs of our customers and their patients.”

In addition to saving facility resources and clinician time during a breast biopsy procedure, the Brevera system’s proprietary CorLumina imaging technology helps enhance workflow across multiple departments within a health system. The technology automates the tissue sample collection and separation process, which allows patient tissue to be sent to pathology with little or no manual handling, and also protects the integrity of samples. The system also features PACS integration for advanced image sharing and transfer of patient records. The Brevera system is designed for use with Hologic’s Affirm prone biopsy system, Affirm breast biopsy guidance system, and MultiCare Platinum system, as well as most upright and prone systems on the market.

1 3D biopsy only when used with the Affirm breast biopsy system.

2 2015 Kadence International survey of 200 healthcare professionals.

Source: Hologic


More on the subject:More on companies:
Read all latest stories

Related articles


Article • Digital breast tomosynthesis

Transforming breast screening: The role of AI in improving reading workflow

While having more centers adopt digital breast tomosynthesis (DBT) for breast cancer screenings into their practice is a positive change, it also presents some challenges for…


Article • Supplemental imaging

The next breast screening advancement: Contrast-enhanced mammography

With the recent recommendation changes from the European Council in 2022, how radiologists screen for breast cancer is changing. Mammography has long been an essential technology in screening for…


Article • Digital breast tomosynthesis (DBT)

New EU recommendations for breast screening enhance opportunities for early detection

Mammography has been an essential imaging technology for breast cancer detection for decades. As the industry has continued to innovate, one advancement in mammography has particularly changed the…

Related products

Subscribe to Newsletter